A166480 Share Price Performance
₩2,710.00
-7370.00 (-73.12%)
Price ₩2,710.00
Share Price₩2,710.00
A166480 Community Narratives
There are no narratives available yet.
Recent A166480 News & Updates
No updates
CORESTEMCHEMON Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -693.17
- Gross Margin
- -12.57%
- Net Profit Margin
- -63.75%
- Debt/Equity Ratio
- 99.8%
CORESTEMCHEMON Inc. Competitors
About A166480
- Founded
- 2003
- Employees
- 355
- CEO
- WebsiteView website
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.
South Korean Market Performance
- 7 Days: -0.5%
- 3 Months: 23.2%
- 1 Year: 22.9%
- Year to Date: 31.8%
Over the last 7 days, the market has dropped 1.6%, driven by a pullback of 3.6% in the Information Technology sector. In the last year, the market is actually up 21%. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading